Skip to main content
Top
Published in: The European Journal of Health Economics 4/2018

01-05-2018 | Original Paper

Costs associated with community acquired pneumonia in France

Authors: Grèce Saba, Luiz Flavio Andrade, Jacques Gaillat, Pierre Bonnin, Christian Chidiac, Hajnal-Gabriela Illes, Henri Laurichesse, Jonathan Messika, Jean-Damien Ricard, Bruno Detournay, Patrick Petitpretz, Gérard de Pouvourville

Published in: The European Journal of Health Economics | Issue 4/2018

Login to get access

Abstract

Objectives

Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context.

Methods

Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6. Descriptive statistics and multivariate analyses were performed. We used generalized linear models with log-link functions to estimate parameters associated with hospital and follow-up costs of patients.

Results

Five hundred twenty-four patients were enrolled in 40 public centers from October 2011 to April 2014. Average age was 63 (SD 17); 55.0% of them were male. Average length of stay was 15 days (SD 23). Average cost of stay for the French Sickness Fund was €7293 (SD €7363). Average cost of follow-up was €1242 (SD €3000) and decreased steadily through time. When controlling for patient’s socioeconomic characteristics, severity of disease and hospital stay, results showed a concave relationship between hospital costs and age. Obesity, the severity of the disease and comorbidities were associated with constantly increasing inpatient costs. Concerning follow-up costs, we found the same concave relationship with age, while gender, a history of pneumonia and severity of the disease were the most important predictors of high costs after discharge.

Conclusion

Pneumocost is the first French study providing a robust estimation of the cost of managing invasive pneumococcal pneumonia in the French context.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torres, A., Peetermans, W.E., Viegi, G., Blasi, F.: Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68(11), 1057–1065 (2013)CrossRefPubMedPubMedCentral Torres, A., Peetermans, W.E., Viegi, G., Blasi, F.: Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68(11), 1057–1065 (2013)CrossRefPubMedPubMedCentral
2.
go back to reference Vila-Corcoles, A., Ochoa-Gondar, O., Rodriguez-Blanco, T., Raga-Luria, X., Gomez-Bertomeu, F.: EPIVAC study group. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir. Med. 103(2), 309–316 (2009)CrossRefPubMed Vila-Corcoles, A., Ochoa-Gondar, O., Rodriguez-Blanco, T., Raga-Luria, X., Gomez-Bertomeu, F.: EPIVAC study group. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir. Med. 103(2), 309–316 (2009)CrossRefPubMed
3.
go back to reference Trotter, C.L., Stuart, J.M., George, R., et al.: Increasing hospital admissions for pneumonia, England. Emerg. Infect. Dis. 14, 72733 (2008)CrossRef Trotter, C.L., Stuart, J.M., George, R., et al.: Increasing hospital admissions for pneumonia, England. Emerg. Infect. Dis. 14, 72733 (2008)CrossRef
4.
go back to reference Welte, T., Torres, A., Nathwani, D.: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67, 71–79 (2012)CrossRefPubMed Welte, T., Torres, A., Nathwani, D.: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67, 71–79 (2012)CrossRefPubMed
5.
go back to reference Casez, P., Fauconnier, J., Jorgensen, L., Gutterman, E.M., Gray, S., Munson, S., Dartois, N., Gaillat, J.: Longitudinal DRG-based survey of all-cause and pneumococcal pneumonia and meningitis for inpatients in France (2005–2010). Médecine et Maladies Infectieuses 45, 446–455 (2015)CrossRefPubMed Casez, P., Fauconnier, J., Jorgensen, L., Gutterman, E.M., Gray, S., Munson, S., Dartois, N., Gaillat, J.: Longitudinal DRG-based survey of all-cause and pneumococcal pneumonia and meningitis for inpatients in France (2005–2010). Médecine et Maladies Infectieuses 45, 446–455 (2015)CrossRefPubMed
6.
go back to reference Sato, R., Gomez Rey, G., Nelson, S., Pinsky, B.: Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years. Appl. Health Econ. Health Policy 11(3), 251–258 (2013)CrossRefPubMedPubMedCentral Sato, R., Gomez Rey, G., Nelson, S., Pinsky, B.: Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years. Appl. Health Econ. Health Policy 11(3), 251–258 (2013)CrossRefPubMedPubMedCentral
7.
go back to reference Castiglia, Paolo: Recommendations for pneumococcal immunization outside routine childhood immunization programs in western Europe. Adv. Ther. 31(10), 1011–1044 (2014)CrossRefPubMedPubMedCentral Castiglia, Paolo: Recommendations for pneumococcal immunization outside routine childhood immunization programs in western Europe. Adv. Ther. 31(10), 1011–1044 (2014)CrossRefPubMedPubMedCentral
8.
9.
go back to reference Bonafede, M.M., Suaya, J.A., Wilson, K.L., Mannino, D.M., Polsky, D.: Incidence and cost of CAP in a large working-age population. Am. J. Manag. Care. 18(7), 380–387 (2012)PubMed Bonafede, M.M., Suaya, J.A., Wilson, K.L., Mannino, D.M., Polsky, D.: Incidence and cost of CAP in a large working-age population. Am. J. Manag. Care. 18(7), 380–387 (2012)PubMed
10.
go back to reference Bordon, J., Wiemken, T., Peyrani, P., Paz, M.L., Gnoni, M., Cabral, P., Venero Mdel, C., Ramirez, J.: CAPO study group decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 138(2), 279–283 (2010)CrossRefPubMed Bordon, J., Wiemken, T., Peyrani, P., Paz, M.L., Gnoni, M., Cabral, P., Venero Mdel, C., Ramirez, J.: CAPO study group decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 138(2), 279–283 (2010)CrossRefPubMed
11.
go back to reference Brito, V., Niederman, M.S.: Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new ‘speed limit’? Thorax 65, 944–945 (2010)CrossRefPubMed Brito, V., Niederman, M.S.: Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new ‘speed limit’? Thorax 65, 944–945 (2010)CrossRefPubMed
12.
go back to reference Fine, M.J., Auble, T.E., Yealy, D.M., et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 33, 243–250 (1997)CrossRef Fine, M.J., Auble, T.E., Yealy, D.M., et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 33, 243–250 (1997)CrossRef
15.
go back to reference Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 40(5), 373–383 (1987)CrossRefPubMed Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 40(5), 373–383 (1987)CrossRefPubMed
16.
go back to reference Gaillat, J., Varon, E., Lanotte, P., Lepoutre, A., Pelloux, I., Epaulard, O., Bernard, L., Chavanet, P., Mootien, Y.: Surveillance épidémiologique clinico-microbiologique des infections invasives à pneumocoque de l’adulte (IIP) (SIIPA). Médecine et maladies infectieuses 46, 3–4 (2016)CrossRef Gaillat, J., Varon, E., Lanotte, P., Lepoutre, A., Pelloux, I., Epaulard, O., Bernard, L., Chavanet, P., Mootien, Y.: Surveillance épidémiologique clinico-microbiologique des infections invasives à pneumocoque de l’adulte (IIP) (SIIPA). Médecine et maladies infectieuses 46, 3–4 (2016)CrossRef
17.
go back to reference Weycker, D., Farkouh, R.A., Strutton, D.R., Edelsberg, J., Shea, K.M., Pelton, S.I.: Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Ser. Res. 16, 182 (2016)CrossRef Weycker, D., Farkouh, R.A., Strutton, D.R., Edelsberg, J., Shea, K.M., Pelton, S.I.: Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Ser. Res. 16, 182 (2016)CrossRef
18.
go back to reference Ament, A., Baltussen, R., Duru, G., Rigaud-Bully, C., de Graeve, D., Ortqvist, A., Jönsson, B., Verhaegen, J., Gaillat, J., Christie, P., Salazar Cifre, A., Vivas, D., Loiseau, C., Fedson, D.S.: Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries. Clin. Infect. Dis. 31, 444–450 (2000)CrossRefPubMed Ament, A., Baltussen, R., Duru, G., Rigaud-Bully, C., de Graeve, D., Ortqvist, A., Jönsson, B., Verhaegen, J., Gaillat, J., Christie, P., Salazar Cifre, A., Vivas, D., Loiseau, C., Fedson, D.S.: Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries. Clin. Infect. Dis. 31, 444–450 (2000)CrossRefPubMed
20.
go back to reference Ostermann, H., Garau, J., Medina, J., Pascual, E., McBride, K., Blasi, F., on behalf of the REACH study group: Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm. Med. 14, 36 (2014)CrossRefPubMedPubMedCentral Ostermann, H., Garau, J., Medina, J., Pascual, E., McBride, K., Blasi, F., on behalf of the REACH study group: Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm. Med. 14, 36 (2014)CrossRefPubMedPubMedCentral
21.
go back to reference Bonten, M.J.M., Huijts, S.M., Marieke Bolkenbaas, M., Webber, C., Patterson, S., et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. NJEM 372(12), 1114–1125 (2015)CrossRef Bonten, M.J.M., Huijts, S.M., Marieke Bolkenbaas, M., Webber, C., Patterson, S., et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. NJEM 372(12), 1114–1125 (2015)CrossRef
22.
go back to reference Vissink, C.E., Huijts, S.M., de Wit, G.A., Bonten, M.J.M., Mangen, M.J.J.: Hospitalization costs for community acquired pneumonia in Dutch elderly: an observational study. BMC Infect. Dis. 16, 466 (2016)CrossRefPubMedPubMedCentral Vissink, C.E., Huijts, S.M., de Wit, G.A., Bonten, M.J.M., Mangen, M.J.J.: Hospitalization costs for community acquired pneumonia in Dutch elderly: an observational study. BMC Infect. Dis. 16, 466 (2016)CrossRefPubMedPubMedCentral
23.
go back to reference Sicras-Mainar, A., Ibáñez-Nolla, J., Cifuentes, I., Guijarro, P., Navarro-Artieda, R., Aguilar, L.: Retrospective epidemiological study for the characterization of community-acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). BMC Infect. Dis. 12, 283 (2012)CrossRefPubMedPubMedCentral Sicras-Mainar, A., Ibáñez-Nolla, J., Cifuentes, I., Guijarro, P., Navarro-Artieda, R., Aguilar, L.: Retrospective epidemiological study for the characterization of community-acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain). BMC Infect. Dis. 12, 283 (2012)CrossRefPubMedPubMedCentral
24.
go back to reference Klok, R.M., Lindkvist, R.M., Ekelund, M., Farkouh, R.A., Strutton, D.R.: Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin. Ther. 35(2), 119–134 (2013)CrossRefPubMed Klok, R.M., Lindkvist, R.M., Ekelund, M., Farkouh, R.A., Strutton, D.R.: Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin. Ther. 35(2), 119–134 (2013)CrossRefPubMed
25.
go back to reference Bauer, T.T., Welte, T., Ernen, C., Schlosser, B.M., Thate-Waschke, I., de Zeeuw, J., Schultze-Werninghaus, G.: Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 128(4), 2238–2246 (2005)CrossRefPubMed Bauer, T.T., Welte, T., Ernen, C., Schlosser, B.M., Thate-Waschke, I., de Zeeuw, J., Schultze-Werninghaus, G.: Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 128(4), 2238–2246 (2005)CrossRefPubMed
26.
go back to reference Boccalini, S., Bechini, A., Levi, M., Tiscione, E., Gasparini, R., Bonanni, P.: Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum. Vaccines Immunother. 9(3), 699–706 (2013)CrossRef Boccalini, S., Bechini, A., Levi, M., Tiscione, E., Gasparini, R., Bonanni, P.: Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum. Vaccines Immunother. 9(3), 699–706 (2013)CrossRef
Metadata
Title
Costs associated with community acquired pneumonia in France
Authors
Grèce Saba
Luiz Flavio Andrade
Jacques Gaillat
Pierre Bonnin
Christian Chidiac
Hajnal-Gabriela Illes
Henri Laurichesse
Jonathan Messika
Jean-Damien Ricard
Bruno Detournay
Patrick Petitpretz
Gérard de Pouvourville
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 4/2018
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-017-0900-z

Other articles of this Issue 4/2018

The European Journal of Health Economics 4/2018 Go to the issue